Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822646) titled 'A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Chinese PLA General Hospital
Condition:
Ovarian Cancer
Intervention:
Drug: Manganese Chloride
Drug: Nab-paclitaxel
Drug: Platinum chemotherapy
Drug: Anti-PD-1 antibody
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: October 12, 2026
Target Sam...